Modification of 5-methoxy-N, N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms

[1]  Ruo-qi Zhang,et al.  Xenobiotica the fate of foreign compounds in biological systems , 2016 .

[2]  B. Lendvai,et al.  Effect of a kynurenic acid analog on home-cage activity and body temperature in rats. , 2015, Pharmacological reports : PR.

[3]  U. Głowacka,et al.  Apomorphine enhances harmaline-induced tremor in rats , 2015, Pharmacological reports : PR.

[4]  F. Carvalho,et al.  The hallucinogenic world of tryptamines: an updated review , 2015, Archives of Toxicology.

[5]  A. Yu,et al.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors , 2015, Neuropharmacology.

[6]  A. Halberstadt.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens , 2015, Behavioural Brain Research.

[7]  M. Zarrindast,et al.  Possible involvement of CA1 5-HT1B/1D and 5-HT2A/2B/2C receptors in harmaline-induced amnesia , 2014, Pharmacology Biochemistry and Behavior.

[8]  S. Zorn,et al.  Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats , 2014, Neuropharmacology.

[9]  P. Celada,et al.  The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs. , 2014, The international journal of neuropsychopharmacology.

[10]  R. Borschmann,et al.  Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample , 2014, Journal of psychopharmacology.

[11]  Š. Alušík,et al.  Serotonin syndrome. , 2014, Neuro endocrinology letters.

[12]  L. P. Morin,et al.  Drugs that prevent mouse sleep also block light-induced locomotor suppression, circadian rhythm phase shifts and the drop in core temperature , 2013, Neuroscience.

[13]  M. Fox,et al.  Animal models of the serotonin syndrome: A systematic review , 2013, Behavioural Brain Research.

[14]  R. Tyndale,et al.  Potential role of CYP2D6 in the central nervous system , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  D. Mager,et al.  Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status , 2013, Drug Metabolism and Disposition.

[16]  T. Nishikawa,et al.  Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N, N-diisopropyltryptamine abuser , 2013, Addiction Science & Clinical Practice.

[17]  E. Liebelt,et al.  Recognizing Serotonin Toxicity in the Pediatric Emergency Department , 2012, Pediatric emergency care.

[18]  R. Bruno,et al.  Emerging psychoactive substance use among regular ecstasy users in Australia. , 2012, Drug and alcohol dependence.

[19]  D. E. Nichols,et al.  Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor , 2012, Psychopharmacology.

[20]  M. Geyer,et al.  Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice , 2011, Journal of psychopharmacology.

[21]  Simon L Hill,et al.  Clinical toxicology of newer recreational drugs , 2011, Clinical toxicology.

[22]  J. C. Winter,et al.  Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice , 2011, Pharmacology Biochemistry and Behavior.

[23]  R. Strassman,et al.  Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. , 2011, Biomedical chromatography : BMC.

[24]  Adam L. Halberstadt,et al.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens , 2011, Neuropharmacology.

[25]  V. Risbrough,et al.  Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT1A receptor knockout mice: Implications for schizophrenia , 2011, Neuropharmacology.

[26]  J. C. Winter,et al.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. , 2010, Current drug metabolism.

[27]  A. Yu,et al.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. , 2010, Biochemical pharmacology.

[28]  Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule. , 2010, Federal register.

[29]  A. Yu,et al.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. , 2009, Biochemical pharmacology.

[30]  A. Helander,et al.  Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials , 2009, Clinical toxicology.

[31]  A. Yu,et al.  Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study. , 2009, Bioanalysis.

[32]  S. Smolinske,et al.  Foxy methoxy: A new drug of abuse , 2005, Journal of Medical Toxicology.

[33]  M. Geyer,et al.  Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors , 2008, Psychopharmacology.

[34]  A. Yu.  Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions , 2008, The AAPS Journal.

[35]  J. Horáček,et al.  Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose , 2007, Psychopharmacology.

[36]  K. Honda,et al.  A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. , 2006, Forensic science international.

[37]  M. Geyer,et al.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats , 2006, Psychopharmacology.

[38]  M. Geyer,et al.  Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol , 2006, Psychopharmacology.

[39]  B. Levine,et al.  A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. , 2005, Journal of analytical toxicology.

[40]  Allison A. Muller.  New drugs of abuse update: Foxy Methoxy. , 2004, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.

[41]  D. Mckenna.  Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. , 2004, Pharmacology & therapeutics.

[42]  E. Boyer,et al.  Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances , 2004, Journal of toxicology. Clinical toxicology.

[43]  Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule. , 2004, Federal register.

[44]  D. Spencer,et al.  Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine , 2004, Psychopharmacology.

[45]  J. Idle,et al.  Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. , 2003, Pharmacogenetics.

[46]  R. Hoffman,et al.  Alpha-methyltryptamine revisited via easy Internet access. , 2003, Veterinary and human toxicology.

[47]  J. Idle,et al.  Contribution of Individual Cytochrome P450 Isozymes to theO-Demethylation of the Psychotropic β-Carboline Alkaloids Harmaline and Harmine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[48]  J. Ott.  Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine , 2001, Journal of psychoactive drugs.

[49]  J. C. Winter,et al.  The Paradox of 5-Methoxy-N,N-Dimethyltryptamine An Indoleamine Hallucinogen That Induces Stimulus Control Via 5-HT1A Receptors , 2000, Pharmacology Biochemistry and Behavior.

[50]  Kinzo Matsumoto,et al.  Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats. , 1997, General pharmacology.

[51]  B. Roth,et al.  High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. , 1997, The Journal of pharmacology and experimental therapeutics.

[52]  H A Ball,et al.  Validation of a telemetry system for measurement of blood pressure, electrocardiogram and locomotor activity in beagle dogs. , 1997, Clinical and experimental hypertension.

[53]  Kinzo Matsumoto,et al.  Hypothermic effect of harmala alkaloid in rats: Involvement of serotonergic mechanism , 1995, Pharmacology Biochemistry and Behavior.